Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05055609 | Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | recruiting | Phase 1 | 94 | TretheraINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05161390 | Study of LM-302 in Patients With Advance Solid Tumors | completed | Phase 1 / Phase 2 | 153 | LaNova Medicines Zhejiang Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05199753 | Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 78 | LaNova Australia Pty LimitedINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06868199 | A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 87 | LaNova Medicines LimitedINDUSTRY | 2 | Sep 12, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07170787 | A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 104 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04632108 | A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 199 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05357651 | A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001) | recruiting | Phase 1 | 100 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05707676 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors(MEETCD8-001)(MEETCD8-001) | terminated | Phase 1 | 40 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06468358 | A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors(TRIGGERCD8) | recruiting | Phase 1 / Phase 2 | 194 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06226766 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | terminated | Phase 1 / Phase 2 | 11 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06187402 | A Study of LM-24C5 For Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | LaNova Medicines LimitedINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06783569 | A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors | recruiting | Phase 1 | 94 | JiaRay GroupINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05723640 | The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | completed | Phase 1 | 11 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07158918 | ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | ABL Bio, Inc.INDUSTRY | 3 | Sep 8, 2025 | clinicaltrials |
| NCT05932862 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 429 | ExelixisINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06209580 | AMT-253 in Patients With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 96 | Multitude Therapeutics Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07156253 | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07157956 | CVL006 Combination Therapy in Advanced Solid Tumors(CVL006-T1002) | not yet recruiting | Phase 1 / Phase 2 | 318 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04418167 | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | suspended | Phase 1 | 71 | JS InnoPharm, LLCINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06873659 | SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 96 | Qurgen Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07067567 | A Study of AK146D1 for Injection in Advanced Solid Tumors | recruiting | Phase 1 | 200 | AkesoINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT04685226 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 310 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04989387 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 57 | Incyte CorporationINDUSTRY | 6 | Sep 2, 2025 | clinicaltrials |
| NCT05063318 | Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | PharmaMarINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05114668 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | Kazia Therapeutics LimitedINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05490043 | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 33 | Antengene (Hangzhou) Biologics Co., Ltd.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT07142837 | Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 153 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05578872 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | completed | Phase 1 / Phase 2 | 29 | Anaveon AGINDUSTRY | 5 | Aug 26, 2025 | clinicaltrials |
| NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | completed | Phase 1 | 13 | Cytosite Biopharma Inc.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT04970992 | A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Da Zen Theranostics IncINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05494918 | First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors | completed | Phase 1 | 62 | Alphamab (Australia) Co Pty Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05835609 | PM534 Administered Intravenously to Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | PharmaMarINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06074705 | A Study of DS-1471a In Subjects With Advanced Solid Tumors | terminated | Phase 1 | 17 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT07056556 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07136558 | Evaluation of ICP-B794 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 410 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT07135128 | A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 20 | Xiaorong SunOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT05109442 | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | terminated | Phase 1 / Phase 2 | 112 | Affimed GmbHINDUSTRY | 5 | Aug 20, 2025 | clinicaltrials |
| NCT07132957 | A Study of AL8326 in Healthy Subjects | completed | Phase 1 | 6 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.(EIK1004-001) | recruiting | Phase 1 / Phase 2 | 130 | Eikon TherapeuticsINDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT05725291 | AMT-116 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Multitude Therapeutics Inc.INDUSTRY | 3 | Aug 17, 2025 | clinicaltrials |
| NCT05761223 | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | recruiting | Phase 1 / Phase 2 | 151 | 1ST Biotherapeutics, Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 12, 2025source: clinicaltrials